The transgenic construct contains a tetracycline-controlled transactivator (tTA), followed by a P2A self cleaving peptide, an EGFP/modified Capzb (capping actin protein of muscle Z-line subunit beta) fusion protein, and a polyA sequence under the control of the 7 kb mouse Arc (activity regulated cytoskeletal-associated protein) promoter. EGFP-CapZ retains native C-terminus region that caps F-actin and binds other major binding proteins. The beta2 splice variant is expressed primarily in the brain and less so in striated muscle, which has Capz in the Z disc. (J:296392)